Kilonzo Mary M, Brown Steven R, Bruhn Hanne, Cook Jonathan A, Hudson Jemma, Norrie John, Watson Angus J M, Wood Jessica
Health Economics Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK.
Surgery Sheffield Teaching Hospitals, Sheffield, UK.
Pharmacoecon Open. 2018 Sep;2(3):271-280. doi: 10.1007/s41669-017-0052-1.
Our objective was to compare the cost effectiveness of stapled haemorrhoidopexy (SH) and traditional haemorrhoidectomy (TH) in the treatment of grade II-IV haemorrhoidal disease from the perspective of the UK national health service.
An economic evaluation was conducted alongside an open, two-arm, parallel-group, pragmatic, multicentre, randomised controlled trial conducted in several hospitals in the UK. Patients were randomised into either SH or TH surgery between January 2011 and August 2014 and were followed up for 24 months. Intervention and subsequent resource use data were collected using case review forms and questionnaires. Benefits were collected using the EQ-5D-3L (EuroQoL-five dimensions-three levels) instrument. The primary economic outcome was incremental cost measured in pounds (£), year 2016 values, relative to the incremental benefit, which was estimated using quality-adjusted life-years (QALYs). Cost and benefits accrued in the second year were discounted at 3.5%. The base-case analysis was based on imputed data. Uncertainty was explored using univariate sensitivity analyses.
Participants (n = 777) were randomised to SH (n = 389) or TH (n = 388). The mean cost of SH was £337 (95% confidence interval [CI] 251-423) higher than that of TH and the mean QALYs were -0.070 (95% CI -0.127 to -0.011) lower than for TH. The base-case cost-utility analysis indicated that SH has zero probability of being cost effective at both the £20,000 and the £30,000 threshold. Results from the sensitivity analyses were similar to those from the base-case analysis.
The evidence suggests that, on average, the total mean costs over the 24-month follow-up period were significantly higher for the SH arm than for the TH arm. The QALYs were also, on average, significantly lower for the SH arm. These results were supported by the sensitivity analyses. Therefore, in terms of cost effectiveness, TH is a superior surgical treatment for the management of grade II-IV haemorrhoids when compared with SH.
本研究旨在从英国国家医疗服务体系的角度,比较吻合器痔上黏膜环切术(SH)和传统痔切除术(TH)治疗Ⅱ-Ⅳ度痔病的成本效益。
在英国多家医院开展了一项开放、双臂、平行组、实用、多中心随机对照试验,并进行了经济评估。2011年1月至2014年8月期间,患者被随机分为接受SH手术或TH手术两组,并随访24个月。使用病例审查表和问卷收集干预措施及后续资源使用数据。使用EQ-5D-3L(欧洲五维健康量表-三个等级)工具收集效益数据。主要经济结果是以2016年英镑价值衡量的增量成本,相对于增量效益,增量效益使用质量调整生命年(QALY)进行估算。第二年产生的成本和效益按3.5%进行贴现。基础病例分析基于估算数据。通过单因素敏感性分析探讨不确定性。
777名参与者被随机分为SH组(n = 389)或TH组(n = 388)。SH的平均成本比TH高337英镑(95%置信区间[CI] 251-423),平均QALY比TH低0.070(95% CI -0.127至-0.011)。基础病例成本效用分析表明,在20000英镑和30000英镑的阈值下,SH具有成本效益的概率为零。敏感性分析结果与基础病例分析结果相似。
证据表明,平均而言,在24个月的随访期内,SH组的总平均成本显著高于TH组。SH组的平均QALY也显著更低。敏感性分析支持了这些结果。因此,在成本效益方面,与SH相比,TH是治疗Ⅱ-Ⅳ度痔更优的手术方法。